#USA #New York #Class Action #Ultragenyx #RARE

Ultragenyx Pharmaceutical Inc. Investors Alert: Class Action Details and Deadline

Ultragenyx Pharmaceutical Inc. Class Action Overview

In recent news, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is currently facing a class-action lawsuit, which has been brought to the attention of its investors by the law firm Levi & Korsinsky, LLP. This lawsuit aims to help investors who have incurred losses due to alleged securities fraud between August 3, 2023, and December 26, 2025. The lead plaintiff deadline for this case is set for April 6, 2026.

Background of the Lawsuit

The case stems from several misleading statements made by the company regarding the potential of its experimental drug, setrusumab. According to the allegations, while Ultragenyx portrayed the drug positively to stakeholders, it suppressed crucial information concerning the drug's efficacy and the actual risks involved in clinical trials. Despite claims that setrusumab could enhance bone density, the results showed no significant reduction in annualized fracture rates—a fundamental aspect highlighted in the company’s ambitious projections.

On December 29, 2025, Ultragenyx announced disappointing results from its Phase III studies known as Orbit and Cosmic, which failed to meet their primary endpoints as initially claimed. The stock, which was trading at $34.19 per share, plummeted to around $19.72, marking a dramatic 42.32% drop in a single day.

Legal Representation and Options for Investors

For those affected, Levi & Korsinsky is encouraging Ultragenyx investors to come forward and participate in the lawsuit without any out-of-pocket legal fees. Interested investors have until April 6, 2026, to request appointment as lead plaintiff, though there are no requirements to do so in order to be part of the eventual recovery process.

Joseph E. Levi, a representative from the firm, is available for consultations through email or phone for those seeking more information regarding their claims.

Why Choose Levi & Korsinsky?

With a rich history of representing investors, Levi & Korsinsky has a proven track record in securities litigation, with over 70 dedicated professionals aiming to secure reparations for their clients. They have been consistently ranked among the top securities litigation firms in the United States, having secured hundreds of millions of dollars for investors over two decades.

Conclusion

Investors in Ultragenyx Pharmaceutical Inc. should be aware of the ongoing class action lawsuit that could provide them with a potential path for restitution. If you’ve suffered losses due to the allegations of misleading statements and the subsequent decline in stock value, the current climate presents an opportunity to seek legal recourse. For further details, contacting Levi & Korsinsky may clarify your options moving forward.